The number of biosimilars being introduced in Canada is growing rapidly. These medications are similar to the reference biologic but are not exact copies. Biosimilars are being used in the management of diabetes, cancer and autoimmune inflammatory disorders. Specialists and primary care clinicians are increasingly being asked questions about these products and how they compare to the reference biologic in terms of efficacy and safety.
This program is designed to address the key questions regarding biosimilars and their place in therapy. The goal is for all participants to be able to answer the key questions clinicians and patients may have regarding this class of medications whose use is increasing.